TO
Therapeutic Areas
Takara Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TBI-1401 (HSV-TK/GCV) | Hematological malignancies (haploidentical HSCT) | Phase 3 |
| TBI-1501 (Anti-CD19 CAR-T) | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1/2 |
| TBI-1301 (NY-ESO-1 TCR Gene Therapy) | Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 1/2 |
| Gene Therapy for ADA-SCID | Adenosine Deaminase Deficiency Severe Combined Immunodeficiency | Preclinical |
| Allogeneic iPS Cell-derived NK Cell Therapy | Solid Tumors | Research |
Leadership Team at Takara Bio
KN
Koichi Nakao
Representative Director, President & Chief Executive Officer (CEO)
HT
Hidemasa Tonai
Director, Senior Managing Executive Officer
YO
Yoshihiko Oka
Director, Senior Managing Executive Officer
TY
Takeshi Yamamoto
Director, Managing Executive Officer, President of Gene Therapy Business Division
MT
Masanori Terashima
Director, Managing Executive Officer
SK
Shinichi Kurosawa
Director, Managing Executive Officer, President of Bioindustry Business Division
KT
Kazunori Tsuchiya
Director, Managing Executive Officer
YS
Yutaka Shibata
Standing Corporate Auditor
KN
Kazuko Nishimura
Corporate Auditor
MO
Mitsuyo Onuma
Corporate Auditor